recursion
-
Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks
REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp…
-
Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia
Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia
-
Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference
Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference
-
Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More
Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies,…
-
Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability
Recursion reported initial monotherapy dose-escalation data from the Phase 1/2 study (ELUCIDATE) of REC-617, a selective CDK7 inhibitor,…
-
Recursion announces first patient dosed in Phase 1/2 clinical study of REC-1245, a potential first-in-class, RBM39 degrader for Biomarker-Enriched Solid Tumors and Lymphoma
First program to result from end-to-end use of OS to identify a novel target and new chemical matter,…
-
Recursion and Exscientia Shareholders Approve the Proposed Combination
Update call scheduled for November 20th at 7:30 a.m. Eastern with anticipated close
-
Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud’s Model Garden
OpenPhenom is a non-commercial, publicly available foundation model built on microscopy data that has set the new “gold…
-
Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability
REC-994 also demonstrates encouraging trends in objective MRI-based exploratory efficacy measures at the highest dose and the company…
-
A former legislator and a biotech executive join Tribune’s board of directors
Rebecca Chavez-Houck and Chris Gibson bring unique perspectives to board that oversees the nonprofit news outlet, they said.
-
Power of Recursion OS on Display at Genome Scale in Nature Genetics Paper Detailing Potential Limitation of CRISPR Gene Editing Tool
Published open-access today in Nature Genetics, “High-resolution genome-wide mapping of chromosome-arm-scale truncations induced by CRISPR–Cas9 editing” identifies novel…
-
Recursion Announces Completion of NVIDIA-Powered BioHive-2, the Largest Supercomputer in Pharmaceutical Industry
BioHive-2, an NVIDIA DGX SuperPOD with NVIDIA DGX H100 systems, ranked #35 in the TOP500 list of the…
Call to Action
Post Category
- BioUtah COVID-19 Analysis
- BioUtah News
- Business Tools & Resources
- Call to Action
- chair
- COVID-19 Legislation
- COVID-19 Updates
- Economic Developments
- Events
- Events
- Feature
- Featured Members
- Federal News
- Funding
- Funding
- Guests Posts
- HHS/FDA & Other Regulatory
- HR
- Industry News
- Life Sciences Events
- Life Sciences Industry News
- Newsletters
- Non-chair
- Policy News
- Press Releases
- State News
- Utah's Life Sciences Companies
- Workplace Safety
Latest Posts
- Lumea Named Best New Biopsy Technology Solution in 2026 MedTech Breakthrough Awards
- Co-Diagnostics Develops Ebola Assay Strategy Following Recent Global Outbreak Alert
- BlueWind Medical Secures $47.8 Million Financing to Accelerate Commercialization of Revi® System
- PhotoPharmics Announces Last Patient Last Visit in Pivotal, Phase 3, Light for PD Clinical Trial; Company to Present Topline Data at World Parkinson Congress
- AFTER SUCCESSFUL FDA MEETING, CLENE FILING ACCELERATED APPROVAL NDA FOR ALS
